Docoh
Loading...

CLSN Celsion

News

From Benzinga Pro
CLSN: OVATION 2 Trial Nears 70% of Target Enrollment…
17 Nov 21
Penny Stocks
By David Bautz, PhD NASDAQ:CLSN READ THE FULL CLSN RESEARCH REPORT
Celsion Q3 EPS $(0.06) Beats $(0.08) Estimate
15 Nov 21
Earnings, News
Celsion (NASDAQ:CLSN) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.08) by 25 percent. This is a 64.71 percent increase over losses of $(0.17) per share from the same
Earnings Scheduled For November 15, 2021
15 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its third quarter.
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
20 Oct 21
Pre-Market Outlook, Markets, Movers
18 Stocks Moving in Tuesday's Pre-Market Session
19 Oct 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 26.1% to $2.03 in pre-market trading after surging 18% on Monday. Kaival Brands Innovations recently announced plans to launch distribution of its products in the U.K.
Celsion Reports Will Give Oral Presentation At Int'l. Vaccine Congress Monday, Oct. 18 At 7:30 a.m. EDT
15 Oct 21
News, Events
Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA mediated immunotherapy and next-generation nucleic vaccines, announces that a time of Monday, October 18, 2021 at 7:30 a.m. Eastern
Celsion Corporation Announces Oral Presentation At International Vaccines Congress
12 Oct 21
News, FDA, Events
Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA mediated immunotherapy and next-generation nucleic vaccines, announces that Khursheed Anwer, Ph.D., executive vice president and
CLSN: Initiating Coverage of Celsion Corporation; Novel DNA-Based Cancer Immunotherapy Technology…
11 Oct 21
Penny Stocks
By David Bautz, PhD NASDAQ:CLSN READ THE FULL CLSN RESEARCH REPORT
Celsion Shares Spike To Session High Near $1, Up 9.5% As Traders Circulate Zack's Small Cap Research Note Showing Initiation Of Stock With $3.50 Price Target
11 Oct 21
Analyst Color, Price Target, Analyst Ratings, Movers, Trading Ideas
https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Research_10112021_CLSN_Bautz.pdf
Celsion GmbH Announces Publication Of Article Reviewing History Of ThermoDox Drug Development In Advanced Drug Delivery Reviews
11 Oct 21
News, FDA
Celsion GmbH, a wholly owned subsidiary of Celsion Corporation (NASDAQ: CLSN), a clinical-stage biotechnology company focused on DNA-based immunotherapy and next-generation vaccines, announces the
12 Health Care Stocks Moving In Monday's Pre-Market Session
11 Oct 21
Pre-Market Outlook, Markets, Movers
Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares moved upwards by 89.3% to $34.53 during Monday's pre-market session. The market value of their outstanding shares is at $1.6 billion.
3 Penny Stocks Insiders Are Buying
11 Oct 21
News, Penny Stocks, Insider Trades, Pre-Market Outlook, Markets, Trading Ideas
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Celsion Corporation Announces New Management Appointments
5 Oct 21
News, Management
Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces the strengthening of its management team with a new hire and a promotion
Celsion, Hainan Poly Pharm Sign Agreement To Manufacture Celsion's DNA-Based Vaccine; Terms Not Disclosed
17 Sep 21
News, Contracts
Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, and Hainan Poly Pharm Co. Ltd. (Shenzhen Stock Exchange 300630.SZ), a generics